Tag Archives: Star Scientific

Star Scientific Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fi

By Business Wirevia The Motley Fool

Filed under:

Star Scientific Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

DALLAS–(BUSINESS WIRE)– Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action lawsuit has been filed in Virginia against Star Scientific, Inc. (“Star Scientific” or “Company”) (NasdaqGM: STSI) and several of its officers and directors for acts taken during the period of October 31, 2011 to March 18, 2013 (the “Class Period”).

Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Star Scientific. If you are an affected Star Scientific shareholder and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zach Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at zach@powerstaylor.com. There is no cost or fee to you.

In the complaint, the defendants are alleged to have violated provisions of the Securities Exchange Act of 1934. Notably, one of the complaints alleges that defendants misrepresented and/or failed to disclose that, among other things: (1) the Company engaged in potentially illegal transactions involving certain private placements and related party transactions since 2006; and (2) the Company received subpoenas from the US Attorney’s office investigating potential securities fraud involving transactions dating back to 2006. According to this complaint, when these facts were finally disclosed, Star Scientific‘s shares dropped substantially.

“The allegedly improper business practices conducted by Star Scientific have prompted our firms to investigate additional claims against the Company’s officers and directors, including potential breaches of fiduciary duties and other violations of state law. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of Star Scientific stock for all shareholders,” said shareholder rights attorney Patrick Powers.

The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

…read more

Source: FULL ARTICLE at DailyFinance

Investor Alert: Hagens Berman Notifies Star Scientific, Inc. Investors of Class Action and May 24th

By Business Wirevia The Motley Fool

Filed under:

Investor Alert: Hagens Berman Notifies Star Scientific, Inc. Investors of Class Action and May 24 th Lead Plaintiff Deadline

BERKELEY, Calif.–(BUSINESS WIRE)– Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is notifying investors in Star Scientific, Inc. (NAS: STSI) (“STSI” or “the Company”) of the filing of a securities class-action lawsuit seeking to recover losses. Investors who have suffered losses may contact the firm by emailing STSI@hbsslaw.com.

If you purchased shares of STSI common stock between Oct. 31, 2011, and March 18, 2013, inclusive (the “Class Period“), suffered significant losses and wish to be a lead plaintiff in the pending class action, you may contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000. You can also contact Mr. Kathrein by submitting information at http://www.hb-securities.com/investigations/STSI.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 24, 2013. Any investor during the Class Period may file to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On Jan. 23, 2013, The Street published an article suggesting that STSI‘s claim that John Hopkins University was involved in clinical testing of the company’s nutritional supplement anatabine was false. On March 18, 2013, STSI disclosed that it received subpoenas in January and February of 2013 from the U.S. attorney’s office and was conducting its own internal investigation into possible issues in the trading of its securities as far back as 2006.

Hagens Berman‘s investigation centers around whether STSI was aware of possible issues, failed to disclose those issues as required by the securities laws, and thus issued materially false or misleading statements to investors during the class period.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro, LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm’s …read more
Source: FULL ARTICLE at DailyFinance

These Stocks Need a Bailout of Their Own

By Rich Duprey, The Motley Fool

Filed under:

The tremor sent through the global financial system was almost palpable. The prospects of seizing the bank accounts of individual Cypriot customers in exchange for a bailout could unleash a wave of bank runs around the world before world governments in equally shaky financial zones could seize them, too. Of course, everyone says that won’t happen, but the slippery slope the EU put itself on had the Dow Jones Industrial Average frozen in place, rising a barely perceptible three points yesterday.

The three stocks below faced a run of a different sort as investors turned tail, but don’t go running over the cliff with them like a bunch of lemmings just yet: This could just be a temporary situation. Let’s first see whether they had good reason to fall as panic-fueled routs can sometimes lead to excellent buying opportunities.

Company

% Change

Harvest Natural Resources

(32.6%)

Star Scientific

(17.2%)

Glu Mobile

(9.1%)

Thank you, sir, may I have another?!
I’m no accountant, so the arcana of accounting rules is all Greek to me, and apparently also to the bookkeepers at oil and gas producer Harvest Natural Resources, which said it may have to restate its financials going back several years because of a whole slew of accounting errors it found.

According to its SEC filing, Harvest Natural said not only were there errors related to incorrect capitalization of some lease maintenance costs as well as for internal SG&A costs, but the company’s cash-flow presentation also had an error and some of its long-lived assets have been impaired. Oops. Moreover, it just might also be able to identify “additional material weaknesses.” You think?

On top of everything else, the Venezuelan oil and gas operator said it was going to report a loss of $0.26 per share for all of 2012, a tad worse than the $0.87 per share profit that analysts had been expecting. Oh, and its auditor issued a “going concern” notice, which suggests it has substantial doubt about the driller surviving.

Everything is spinning out of control at Harvest ever since India‘s government rejected its planned $725 million sale of Venezuelan assets to the state-owned Petrodelta. Considering the surprise nature of the disclosures, investors were right to sell en masse. As they say, where there’s one cockroach there’s usually more, and Harvest Natural Resources sounds like it’s in need of an exterminator.

In the spotlight
Dietary supplement maker Star Scientific is also under the magnifying glass following the disclosure that the U.S. Attorney’s Office served it with subpoenas in January and February regarding private stock placements that the company made since 2006, along with various related party transactions.

Star didn’t disclose any more information than that in the annual report it filed yesterday — the last day possible to file it — but the muckraking analysts at Street Sweeper had noted a couple of years ago the uncanny timing of …read more
Source: FULL ARTICLE at DailyFinance

Why Star Scientific Is Poised to Keep Plunging

By Brian Pacampara, Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, smokeless tobacco products specialist Star Scientific has received the dreaded one-star ranking.

With that in mind, let’s take a closer look at Star Scientific and see what CAPS investors are saying about the stock right now.

Star Scientific facts

Headquarters (founded)

Glen Allen, Va. (2000)

Market Cap

$300.0 million

Industry

Personal products

Trailing-12-Month Revenue

$5.4 million

Management

Chairman/President/COO Paul Perito
CEO Jonnie Williams

Trailing-12-Month Return on Equity

(136.3%)

Cash/Debt

$9.5 million / $12.0 thousand

Competitors

GlaxoSmithKline
Pfizer
Vector Group

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 45% of the 322 members who have rated Star Scientific believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, kindly updated our community on the opportunity:

So where does Star stand now? The patent infringement suit against big tobacco is gone for a paltry [$5M] settlement. I have to admit that one scared me a little. These are companies that have tens of billions in discretionary funds at their disposal to make irritants like Star go away forever. [$500M]? Chicken feed. So the fact that Star was only able to chisel out [$5M] is flat out pathetic.

The low-nitrosamine tobacco products are gone as well. So now Star only has unregulated cosmetics and nutraceuticals featuring snake oil anti-inflammatory compound anatabine. … Star can’t make anywhere near enough money off anatabine as a nutraceutical to justify its valuation, and the trials they are running to supposedly garner FDA approval as a drug are fraught with misrepresentation and will likewise fail.

Just a note: Virtually every one of my Star [underperform calls] has been followed shortly afterwards by a startling gap up in share price. Of course, I closed all those red thumbs for a solid positive score. So you might want to buy up some Star shares now but keep your finger on the trigger to sell on the spike.

If you want market-topping returns, you need to protect your portfolio from any undue risk, such as the macro trend that Warren Buffett referred to as “the tapeworm that’s eating at American competitiveness.” Find out what it is in our free report: “What’s Really Eating at America’s Competitiveness.” You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Star Scientific Is Poised to Keep Plunging originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks …read more
Source: FULL ARTICLE at DailyFinance